Personalised care Resources

Debridement is vital in wound bed preparation, creating a clean, moist environment that supports effective healing (Burnett et al, 2021). It facilitates the removal of devitalised tissue, bacteria, and debris, reducing infection risk and promoting healthy tissue growth (Mayer et al, 2024). Multiple debridement techniques exist such as sharp, larval, enzymatic, ultrasound, and surgical, however their use may be limited by required expertise or clinical setting. This article introduces an updated definition of debridement and traces its evolution from traditional methods to modern, patient-friendly technologies, exemplified by the innovative dual-sided monofilament pad, Debrisoft® Duo. It also includes some case series evaluating the effectiveness and practicality of Debrisoft Duo, particularly in managing wounds with persistent fibrous devitalised tissue where conventional sharp debridement is unsuitable.

Asthma is a common chronic respiratory condition with approximately 7.2 million cases diagnosed in the UK. This equates to about eight in every 100 people (Asthma+Lung UK, 2025a). Sadly, asthma deaths are at an all-time high and the UK has some of the worse asthma outcomes in Europe (eurostat, 2025). A recent survey suggests that many patients are not even receiving what is considered to be a ‘basic’ level of asthma care (Asthma+Lung UK, 2022). This article considers what really constitutes ‘good asthma care’ and how exactly this can be achieved in often short, primary care consultations. Patients with asthma can suffer from symptoms such as wheeze, cough, shortness of breath, tight chest, and many will have associated atopic conditions such as hay fever. It is a heterogenous disease, which means that patients experience it differently; no two asthmatic patients are the same and thus treatment and management for asthma should be tailored towards individuals and their needs.

There are three million people living with cancer in the UK, which is predicted to rise to nearly 3.5 million by 2025 (Macmillan Cancer Support, 2024). The GP Contract (NHSE Contract Letter 2024/25) has protected the cancer indicators in the Quality Outcomes Framework (QOF), which are that every person should be offered an opportunity to discuss their diagnosis and be informed of the support available to them from primary care within three months of diagnosis, and a structured cancer care review should be offered within twelve months of diagnosis. General practice nurses (GPNs) already have expertise in long-term condition management and could deliver the same for people living with cancer, but
most do not feel confident to do so. This article includes the author’s personal reflections on her role and the development of personalised care within primary care.

Increasing cancer survival rates and evolving models of care require primary care teams to adapt their practice to meet the needs of people after a cancer diagnosis and completion of treatment. The needs of people after a cancer diagnosis are often complex and require a person-centred, holistic model of care. The ‘NHS Long Term Plan’ sets out the ethos of
personalised care for those living with long-term conditions (LTCs), including cancer. Interventions to support personalised care include cancer care reviews (CCR) in primary care. Recent Quality Outcome Framework guidance for CCR has aimed to personalise the intervention to improve patient experience. General practice nurses (GPNs) are well placed to deliver CCR but need access to education to feel confident and develop competence in this area. There are several resources that have been developed to support CCR as a personalised care intervention. These interventions need further evaluation to assess their impact on patient experience and outcomes.